Quarterly ResultAug 6, 2026, 07:27 AM
Roivant Q1 Net Loss $290.6M; Receives $950M Moderna Settlement
AI Summary
Roivant Sciences Ltd. reported a net loss of $290.6 million for the first fiscal quarter ended June 30, 2026, an increase from $273.9 million in the prior year. The company received an initial $950 million payment from Moderna in July 2026 as part of a $2.25 billion patent infringement settlement, with an additional $1.3 billion contingent on a favorable appeal resolution. Roivant also provided updates on its clinical pipeline, including progress for brepocitinib, IMVT-1402, and mosliciguat, and initiated new international lawsuits against Pfizer and BioNTech.
Key Highlights
- Net loss for Q1 2026 was $290.6 million, compared to $273.9 million in Q1 2025.
- Non-GAAP net loss was $243.7 million for Q1 2026, up from $170.1 million in Q1 2025.
- Received initial $950 million from Moderna in July 2026 from a $2.25 billion patent settlement.
- Consolidated cash, cash equivalents, and marketable securities totaled $3.9 billion as of June 30, 2026.
- Repurchased 7.3 million common shares for approximately $208.7 million in Q1 2026.
- R&D expenses increased by $49.1 million to $202.0 million for the quarter.
- G&A expenses increased by $31.5 million to $165.5 million for the quarter.
- Commercial launch of brepocitinib in dermatomyositis on track for end of September 2026.
Price Impact
More from ROIV